{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:06:30Z","timestamp":1787015190527,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T00:00:00Z","timestamp":1258934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Aim:\u2002<\/jats:bold>\n                    The aim of this study was to ascertain the management of gout by doctors in Malaysia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    A cross\u2010sectional questionnaire survey was carried out among doctors attending rheumatology post\u2010graduate courses, where gout was not a lecture topic.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    A total of 128 questionnaires were analyzed, of which the majority (67: 52.3%) were general practitioners. In the treatment of acute gout, 68.0% use non\u2010selective non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs), 53.9% use selective COX\u20102 inhibitors (coxibs), 66.4% use colchicine and 10.2% use allopurinol (ALLO). In the treatment of chronic gout, 36.7% use NSAIDs, 44.5% use coxibs, 19.5% use colchicine and 93% use ALLO. In both acute and chronic gout, corticosteroids (CS) are not used by over 90% of respondents. Fifty percent would stop ALLO during an acute attack. 95.3% do not start ALLO during an acute attack; 87.5% would start ALLO after the attack, with a median of 14\u2003days afterwards. Once ALLO was started, 54.7% would continue indefinitely. Regarding target urate levels while on treatment, 10.9% would be satisfied with a high normal range, 21.9% middle of the range, 18.0% low normal range and 45.3% anywhere within the normal range. Fifteen percent would treat asymptomatic hyperuricemia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    In Malaysia, anti\u2010inflammatory agents are most commonly used for the treatment of acute and chronic gout, with corticosteroid usage at a low level. However, there are areas of concern regarding the diagnosis of gout and the usage of ALLO which are not consistent with current guidelines.\n                  <\/jats:p>","DOI":"10.1111\/j.1756-185x.2009.01431.x","type":"journal-article","created":{"date-parts":[[2009,11,23]],"date-time":"2009-11-23T10:45:28Z","timestamp":1258973128000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A survey on the management of gout in Malaysia"],"prefix":"10.1111","volume":"12","author":[{"given":"Swan Sim","family":"YEAP","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M. L.","family":"GOH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Chyn","family":"GUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f54d03"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep086"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024091"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem056a"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055251"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1989.tb128510.x"},{"key":"e_1_2_5_10_2","first-page":"1841","article-title":"A survey of current prescribing practices of anti\u2010inflammatory and urate lowering drugs in gouty arthritis in the province of Ontario","volume":"15","author":"Bellamy N","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071530"},{"key":"e_1_2_5_12_2","first-page":"255","article-title":"Diversity of opinions on the management of gout in France. A survey of 750 rheumatologists","volume":"63","author":"Rozenberg S","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"key":"e_1_2_5_13_2","first-page":"147","article-title":"A survey of the management of gout in primary care in Ireland","volume":"101","author":"Owens D","year":"2008","journal-title":"Ir Med J"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085902"},{"key":"e_1_2_5_15_2","first-page":"115","article-title":"A survey of current prescribing practices of anti\u2010inflammatory and urate\u2010lowering drugs in gouty arthritis","volume":"104","author":"Stuart RA","year":"1991","journal-title":"N Z Med J"},{"key":"e_1_2_5_16_2","first-page":"2050","article-title":"A survey of current evaluation and treatment of gout","volume":"33","author":"Schlesinger N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-199702000-00005"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181896b1e"},{"key":"e_1_2_5_19_2","first-page":"2041","article-title":"The management of gout at an academic healthcare center in Beijing: a physician survey","volume":"33","author":"Fang W","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070755"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181896c35"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep087"},{"key":"e_1_2_5_23_2","first-page":"1566","article-title":"Treatment of acute gout in hospitalized patients","volume":"34","author":"Petersel D","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_5_24_2","unstructured":"Available athttp:\/\/www.acadmed.org my\/index.cfm?&menuid=67(accessed on 28 June 2009)."}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2009.01431.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2009.01431.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:08:01Z","timestamp":1697440081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2009.01431.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,23]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1756-185X.2009.01431.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2009.01431.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,23]]},"assertion":[{"value":"2009-11-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}